Revolutionizing Cartilage Treatment with Cell Therapy
BIONCaRT GmbH develops innovative, allogeneic cell therapies for the regeneration of damaged cartilage tissue – new hope for patients with joint problems.
With BIONCaRT
At a Glance
BIONCaRT GmbH – Biotechnology made in Germany, specializing in stem cell-based therapies
At BIONCaRT, we develop innovative, stem cell-based medicines to treat orthopaedic conditions, with a focus on allogeneic therapies for cartilage regeneration.
Driven by scientific excellence, we advance the development, approval, and manufacturing of next-generation cell therapies — for patients around the world.
Cartilage damage in the knee is notoriously difficult to treat. With MesemCart, BIONCaRT is developing a cutting-edge, cell-based therapy that offers new hope for patients.
Our approach uses mesenchymal stromal cells (MSCs) derived from umbilical cord tissue — biologically active, readily available, and without the need for invasive cell harvesting. MesemCart allows for targeted cartilage regeneration in a single procedure, marking a breakthrough in regenerative medicine for knee joint disorders.
- Ready-to-use Allogeneic Therapy
- Less Stress - Just One Surgery Needed
- Also Suitable for Older Patients
MesemCart has been approved for a Phase I/IIa clinical trial. In this early clinical phase, we are evaluating the safety, tolerability, and initial efficacy of our innovative cell therapy for focal cartilage damage in the knee joint – for the first time in patients.
In the study, MesemCart is applied in combination with the collagen membrane Chondro-Gide, a clinically established medical device that is an integral part of the standardized AMIC procedure.
With this study, we are taking the next step on the path to market authorization and toward establishing MesemCart as a new standard of care in the orthopaedic treatment of cartilage defects.
Age Group
18 – 60 Years
Start of Study / Recruitment
Summer 2025
Planned Number of Participants
55 Patients
Indication
Cartilage Damage to the Knee Joint
without existing knee osteoarthritis
News from BIONCaRT GmbH
Driving Innovation Together
If you have any questions about MesemCart or would like to learn more about our treatment options and clinical trial, we are happy to assist you personally and competently.